H.C. Wainwright analyst Andrew Fein expects to see Nuplazid regain momentum following Acadia Pharmaceuticals' Q3 results. As the overhang of the safety concerns around Nuplazid was cleared by the FDA's statement in September, the key commercial question is now whether the company will be able to regain the growth momentum through a number of promotional activities, Fein tells investors in a research note. He expects to see the "normalization of growth in the months ahead" and says Acadia is poised to outperform in 2019. Fein keeps a Buy rating on the shares with a $60 price target.